Login to Your Account

Cerecor Acquires Rights to Merck's Depression Candidate

By Catherine Shaffer
Staff Writer

Friday, April 19, 2013
Cerecor Inc. acquired rights to an NMDA (N-methyl-d-aspartate) antagonist for development in the area of depression from Merck and Co. Inc. The drug, MK-0657, was initially in development at Merck for Parkinson's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription